

June 14, 2018



Navidea to Host Moderated Q&A Webcast with Management

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals (NYSE MKT: NAVB) (Navidea or The Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer (Q&A) Session focused on Navidea's clinical progress in Nonalcoholic Steatohepatitis (NASH) with Jed Latkin, Chief Financial and Operating Officer, and Fred Cope, Ph.D., Chief Scientific Officer of Navidea, on Thursday June 21, 2018 at 5:00 p.m. Eastern Time. Investors are invited to submit NASH-related questions they would like to hear answered to ir@navidea.com or tpatel@edisongroup.com by Wednesday, June 20, 2018.

Event: Navidea IR Q&A Session – June 2018

Date: Thursday, June 21, 2018

Time: 5:00 p.m. Eastern Time

Website: www.navidea.com

For the June IR-focused Q&A Session, Navidea invites all interested investors to submit questions they would like to see asked by Wednesday, June 20, 2018 to ir@navidea.com or tpatel@edisongroup.com.

Details for the webcast link will be made available on the Investor Relations section of Navidea's website at www.navidea.com.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts.

For more information, please visit <http://www.navidea.com>.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20180614006296/en/>

Navidea Biopharmaceuticals

Jed Latkin, 614-551-3416

CFO/COO

jlatkin@navidea.com

or

Edison Advisors

Tirth Patel, 646-653-7035

tpatel@edisongroup.com

Source: Navidea Biopharmaceuticals